Combining IL-17A neutralization with immune checkpoint inhibitors (ICIs) has been shown to not only maintain the anti-tumor efficacy of ICIs but also to inhibit PD-L1 expression in breast cancer cells (210). Here, IL17A is linked to neoplasm.